The 4.5-hour time window for intravenous thrombolysis with intravenous tissue- Type plasminogen activator is not firmly established

Stroke

Volumn 45, Issue 3, 2014, Pages 914-915

  Wechsler, Lawrence R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Stroke; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

BLEEDING; BLOOD CLOT LYSIS; BLOOD VESSEL OCCLUSION; BRAIN BLOOD VESSEL; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DRUG UTILIZATION; EDEMA; HUMAN; LACUNAR STROKE; META ANALYSIS (TOPIC); NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIST; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION; SHORT SURVEY; TREATMENT DURATION; TREATMENT OUTCOME; ARTICLE; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; PATIENT SELECTION; TIME;

STROKE; TISSUE PLASMINOGEN ACTIVATOR;

FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84899137518     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002701     Document Type: Short Survey

References (5)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
2. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute isch- Aemic stroke: An updated systematic review and meta- Analysis. Lancet. 2012;379:2364-2372.
3. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue- Type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-2026.
4. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial. Lancet. 2012;379:2352-2363.
5. Bluhmki E, Chamorro A, DSvalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): Additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8:1095-1102.